EHA 2018 | Detecting MRD at finer scales in CLL
Florence Cymbalista
• 14 Jun 2018
Measurable residual disease (MRD) is becoming increasingly important as a prognostic indicator in a wide variety of hematological malignancies. We interviewed Florence Cymbalista, PhD, from the Hôpital Avicenne, Bobigny, France, about her recent projects that used a highly sensitive MRD detection in chronic lymphocytic leukemia (CLL) treated with FCR chemotherapy. She speaks about the importance of detecting MRD at fine resolutions, since sensitive detection of MRD in the blood implies MRD in the bone marrow, thereby saving the patient an invasive biopsy. This video was recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
